Skip to content

Orgenesis Inc.

Delisted

CIK 1460602fmd_0Y01YJZP30G47M90DQNVXXQRJWManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Dec 01, 2009 to Dec 31, 2024, 59 periods

Latest annual · FY2024

Millions
Total revenues
1
Gross profit
(1)
Operating income
(40)
Net income
(48)
Free cash flow
(17)

Latest quarter · Q4 FY2024

Millions
Total revenues
0
Gross profit
(0)
Operating income
(18)
Net income
(20)
Free cash flow
(2)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2021 to FY2024
-69.2%
Revenue, 5 yearsFY2019 to FY2024
-23.3%
Net income, 5 yearsFY2019 to FY2024
n/m

Orgenesis Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2024FY2023ChangeSource
Revenue$1 million10-K 2026-03-26 · proof
Gross profit-$893,000-$5.7 million10-K 2026-03-26 · proof
Operating income-$39.8 million-$53.6 million10-K 2026-03-26 · proof
Net income-$48.2 million-$55.4 million10-K 2026-03-26 · proof
Cash from operating activities-$17.1 million-$14.8 million10-K 2026-03-26 · proof
Free cash flow-$17.3 million-$16.9 million10-K 2026-03-26 · proof
Total assets$1.4 million$14.6 million-90.7%10-K 2026-03-26 · proof
Total liabilities$38.9 million$35.5 million+9.4%10-K 2026-03-26 · proof
Cash and cash equivalents$78,000$837,000-90.7%10-K 2026-03-26 · proof
What was Orgenesis Inc.'s revenue in fiscal 2024?
Orgenesis Inc. reported revenue of $1 million for fiscal 2024 (the year ended Dec 31, 2024). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
What was Orgenesis Inc.'s gross profit in fiscal 2024?
Orgenesis Inc. reported gross profit of -$893,000 for fiscal 2024 (the year ended Dec 31, 2024), against -$5.7 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
What was Orgenesis Inc.'s operating income in fiscal 2024?
Orgenesis Inc. reported operating income of -$39.8 million for fiscal 2024 (the year ended Dec 31, 2024), against -$53.6 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
What was Orgenesis Inc.'s net income in fiscal 2024?
Orgenesis Inc. reported net income of -$48.2 million for fiscal 2024 (the year ended Dec 31, 2024), against -$55.4 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
What was Orgenesis Inc.'s cash from operating activities in fiscal 2024?
Orgenesis Inc. reported cash from operating activities of -$17.1 million for fiscal 2024 (the year ended Dec 31, 2024), against -$14.8 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
What was Orgenesis Inc.'s free cash flow in fiscal 2024?
Orgenesis Inc. reported free cash flow of -$17.3 million for fiscal 2024 (the year ended Dec 31, 2024), against -$16.9 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
What are Orgenesis Inc.'s total assets?
As of Dec 31, 2024, Orgenesis Inc. reported total assets of $1.4 million, against $14.6 million a year earlier (-90.7%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
What are Orgenesis Inc.'s total liabilities?
As of Dec 31, 2024, Orgenesis Inc. reported total liabilities of $38.9 million, against $35.5 million a year earlier (+9.4%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
What are Orgenesis Inc.'s cash and cash equivalents?
As of Dec 31, 2024, Orgenesis Inc. reported cash and cash equivalents of $78,000, against $837,000 a year earlier (-90.7%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1460602&period_type=annual&limit=5"

Information only, not investment advice.